Discover
LYEL
Lyell Immunopharma, Inc.
12.97
2 x 9.84
2 x 16.21
bid
ask
-
1.08
7.69%
2 @ 04:00 PM
12.97 +0.00 (0.00%)
| Ytd | -57.86% | |
| 1y | 37.54% |
12.56
day range
14.07
8.96
52 week range
45.00
| Open | 13.82 | Prev Close | 14.05 | Low | 12.56 | High | 14.07 | Mkt Cap | 302.64M |
| Vol | 163.85K | Avg Vol | 135.83K | EPS | -13.62 | P/E | N/A | Forward P/E | -0.73 |
| Beta | -0.48 | Short Ratio | 6.15 | Inst. Own | 58.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 16.72 | 200-d Avg | 20.77 | 1yr Est | 1.00 |
| Income Statement | |||
| Operating Expenses | 44.26M | ||
| Research and Development Expense | 36.60M | ||
| Selling, General and Administrative Expense | 9.56M | ||
| Operating Income | -44.26M | ||
| Net Income | -24.15M | ||
| Net Income Common Stock | -24.15M | ||
| Net Income Common Stock (USD) | -24.15M | ||
| Consolidated Income | -24.15M | ||
| Earnings per Basic Share | -1.10 | ||
| Earnings per Basic Share (USD) | -1.10 | ||
| Earnings per Diluted Share | -1.10 | ||
| Earning Before Interest & Taxes (EBIT) | -24.15M | ||
| Earning Before Interest & Taxes (USD) | -24.15M | ||
| Weighted Average Shares | 21.88M | ||
| Weighted Average Shares Diluted | 21.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 92.36M | ||
| Cash and Equivalents (USD) | 92.36M | ||
| Investments | 189.21M | ||
| Investments Current | 163.25M | ||
| Investments Non-Current | 25.95M | ||
| Current Assets | 267.30M | ||
| Property, Plant & Equipment Net | 50.55M | ||
| Total Assets | 350.63M | ||
| Total Debt | 39.49M | ||
| Current Liabilities | 36.95M | ||
| Debt Non-Current | 39.49M | ||
| Total Liabilities | 76.96M | ||
| Accumulated Retained Earnings (Deficit) | -1.64B | ||
| Accumulated Other Comprehensive Income | -9.00K | ||
| Shareholders Equity | 273.67M | ||
| Shareholders Equity (USD) | 273.67M | ||
| Assets Non-Current | 83.32M | ||
| Total Debt (USD) | 39.49M | ||
| Liabilities Non-Current | 40.01M | ||
| Trade and Non-Trade Payables | 5.47M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.33M | ||
| Net Cash Flow from Financing | 51.72M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 30.59M | ||
| Capital Expenditure | -89.00K | ||
| Issuance (Purchase) of Equity Shares | 1.72M | ||
| Net Cash Flow from Investing | 17.38M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 17.47M | ||
| Net Cash Flow from Operations | -38.51M | ||
| Share Based Compensation | 4.30M | ||